A turkey tails polysaccharide as an immunochemotherapy agent in cancer

Alternative and Complementary Therapies

Volumn 13, Issue 4, 2007, Pages 178-182

  Abascal, Kathy ^a   Yarnell, Eric ^b,c  

^a Botanical Medicine Academy   (United States)

^b Botanical Medicine Academy

^c BASTYR UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FLUOROURACIL; KRESTIN; PLACEBO; POLYSACCHARIDE KRESTIN; TEGAFUR; UNCLASSIFIED DRUG; VPS;

BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; COLORECTAL CANCER; DENDRITIC CELL; DRUG EFFECT; DRUG EFFICACY; DRUG ISOLATION; ESOPHAGUS CANCER; HELPER CELL; HUMAN; LUNG CANCER; MULTIPLE CYCLE TREATMENT; REVIEW; STOMACH CANCER; TRAMETES VERSICOLOR;

EID: 34548063766     PISSN: 10762809     EISSN: None     Source Type: Journal    
DOI: 10.1089/act.2007.13410     Document Type: Review

References (28)

1. Ho CY, Lau CBS, Kim CF, et al. Differential effect of Coriolus versicolor (Yunzhi) extract on cytokine production by murine lymphocytes in vitro. Intern Immunopharmacol 2004;4:1549-1557.
2. Kidd PM. The use of mushroom glucans and proteoglycans in cancer treatment. Altern Med Rev 2000;5:4-27.
3. Kondo M, Torisu M. Evaluation of an anticancer activity of a protein-bound polysaccharide PS-K (Krestin). In: Torisu M, Yoshida T, eds. Basic Mechanisms and Clinical Treatment of Tumor Metastasis. New York: Academic Press, 1985.
4. Torisu M, Hayashi Y, Ishimitsu T, et al. Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer. Cancer Immunol Immunother 1990;31:261-268.
5. Kaibara N, Soejima K, Nakamura T, et al. Clinical value of immunochemotherapy with OK-432. Jpn J Surg 1976;6:54-59.
6. Hattori T, Niimoto M, Koh T, et al. PSK and FT-207 in gastric cancer patients. Jpn J Surg 1979;9:110-117.
7. Kodama Y, Kano T, Tamada R, et al. Combined effect of prophylactic lymphadenectomy and long-term combination chemotherapy for curatively resected carcinoma of the stomach. Jpn J Surg 1982;12:244-248.
8. Niimoto M, Hattori T, Tamada R, et al. Postoperative adjuvant immunochemotherapy with mitomycin C, futraful and PSK for gastric cancer: An analysis of data on 579 patients followed for five years. Jpn J Surg 1988;18:681-686.
9. Tsujitani S, Kakeji Y, Orita H, et al. Postoperative adjuvant immunochemotherapy and infiltration of dendritic cells for patients with advanced gastric cancer. Anticancer Res 1992;12:645-648.
10. Fujimoto S, Takahashi M, Minami T, et al. Clinical value of immunochemotherapy with OK-432. Jpn J Surg 1979;3:190-196.
11. Mitomi T, Ogoshi K. Clinical study of PSK as an adjuvant immunochemotherapeutic agent against gastric cancer. Jpn J Cancer Chemother 1986;13:2532-2537.
12. Nakazato H, Koike A, Saji S, et al. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet 1994;343:1122-1126.
13. Ito K, Nakazato H, Koike A, et al. Long-term effect of 5-fluorouracil enhanced by intermittent administration of polysaccharide K after curative resection of colon cancer. Int J Colorectal Dis 2002;19:157-164.
14. Mitomi T, Tsuchiya S, Iijma N, et al. Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. Dis Colon Rectum 1992;35:123-130.
15. Kudo S, Tanaka J, Kashida H, et al. Effectiveness of immunochemotherapy with PSK, a protein-bound polysaccharide, in colorectal cancer and changes of tumor marker. Oncol Rep 2002;9:635-638.
16. Ohwada S, Ikeya T, Yokomori T, et al. Adjuvant immunochemotherapy with oral Tegafur/ Uracil plus PSK in patients with stage II or III colorectal cancer: A randomized controlled study. Br J Cancer 2004;90:1003-1010.
17. Sakamoto J, Morita S, Oba K, et al. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colon cancer: A meta-analysis of centrally randomized controlled clinical trials. Cancer Immunol Immunother 2006;55:404-411.
18. Okudaira Y, Sugimachi K, Inokuchi K, et al. Postoperative long-term immunochemotherapy for esophageal cancer. Jpn J Surg 1982;12:249-256.
19. Ogoshi K, Satou H, Isono K, et al. Possible predictive markers of immunotherapy in esophageal cancer: Retrospective analysis of a randomized study. Cancer Invest 1995;13:363-369.
20. Go P, Chung CH. Adjuvant PSK immunotherapy in patients with carcinoma of the nasopharynx. J Int Med Res 1989;17:141-149.
21. Hayakawa K, Mitsuhashi N, Saito Y, et al. Effect of Krestin (PSK) as adjuvant treatment on the prognosis after radical radiotherapy in patients with non-small cell lung cancer. Anticancer Res 1993;13:1815-1820.
22. Sugimachi K, Inokuchi K, Matsuura H, et al. Hormone conditioned cancer chemotherapy for recurrent breast cancer prolongs survival. Jpn J Surg 1984;14:217-221.
23. Iino Y, Yokoe T, Maemura M, et al. Immunochemotherapies versus chemotherapy as adjuvant treatment after curative resection of operable breast cancer. Anticancer Res 1995;15:2907-2912.
24. Yokoe T, Iino Y, Takei H, et al. HLA antigen as predictive index for the outcome of breast cancer patients with adjuvant immunochemotherapy with PSK. Anticancer Res 1997;17:2815-2818.
25. Ohno R, Yamada K, Masaoka T, et al. A randomized trial of chemoimmunotherapy of acute nonlymphocytic leukemia in adults using a protein-bound polysaccharide preparation. Cancer Immunol Immunother 1984;18:149-154.
26. Okuzawa M, Shinohara H, Kobayashi T, et al. PSK, a protein-bound polysaccharide, overcomes defective maturation of dendritic cells exposed to tumor-derived factors in vitro. Int J Oncol 2002;20:1189-1195.
27. Borchers AT, Keen CL, Gershwin ME. Mushrooms, tumors, and immunity: An update. Exp Biol Med 2004;229:393-406.
28. No author listed. MushroomScience. Online document at: www.mushroomscience.com/ Accessed May 22, 2007.